Deferiprone targets aconitase: implication for Friedreich's ataxia treatment
about
Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examplesImpaired nuclear Nrf2 translocation undermines the oxidative stress response in Friedreich ataxiaCombined therapy with idebenone and deferiprone in patients with Friedreich's ataxia.Past, present and future therapeutics for cerebellar ataxias.Mesenchymal stem cells restore frataxin expression and increase hydrogen peroxide scavenging enzymes in Friedreich ataxia fibroblastsFriedreich ataxia: molecular mechanisms, redox considerations, and therapeutic opportunities.Frataxin and mitochondrial FeS cluster biogenesis.Impaired iron status in aging researchMitochondrial metals as a potential therapeutic target in neurodegeneration.Fixing frataxin: 'ironing out' the metabolic defect in Friedreich's ataxiaThe emerging role of iron dyshomeostasis in the mitochondrial decay of aging.Current and emerging treatment options in the management of Friedreich ataxia.Dysregulation of iron metabolism in Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis.Deferiprone for the treatment of Friedreich's ataxia.Chemical screening identifies ATM as a target for alleviating senescence.Mesenchymal Stem Cell-Derived Factors Restore Function to Human Frataxin-Deficient Cells.Chemical screening identifies ROCK as a target for recovering mitochondrial function in Hutchinson-Gilford progeria syndrome.Development and Validation of a Terbium-Sensitized LuminescenceAnalytical Method for Deferiprone.Inhibition of prostate cancer proliferation by Deferiprone.Deferiprone in Friedreich ataxia: a 6-month randomized controlled trial.Emerging therapeutics for the treatment of Friedreich’s ataxia
P2860
Q24289511-38FA2C8A-D3DF-4667-81F6-E25A179AAFB9Q28474531-4B86A82E-E558-4F71-912E-A80CB9524CE4Q33701891-0F72368C-6C3B-45B0-BF37-049EFB93B1A8Q33836935-511D7073-3E0A-4091-92BB-AA81DC0F0742Q34053510-A27AE711-70C7-4CF7-A7CD-EFB06936F79DQ34076650-6FC84E2C-B0E6-4F88-B00F-7AAEEE931F30Q34094277-4C9BE1E1-5AA1-4411-A4DD-3543C69BF09FQ35795910-BCF76786-FB36-4DA2-9013-C1E1FB3D4052Q37686294-6061D1F5-7C56-49C6-B03A-57D2640A197FQ37686297-0E7F39E0-C320-4B02-AFE5-ECE23BED153DQ37740429-D89838D1-448E-4CAC-933D-ADD424E1B820Q37790615-0CE52EFF-FE52-46F1-910F-8B28254C445AQ37947588-D8329D7D-4EEB-496C-B8D0-D3CC41CE5D1EQ38121950-1E105384-CC67-4FC7-AC2D-AE710A15FCD6Q38873970-A6942CBC-9BF8-4A69-91B0-6F50EBD9A798Q40956615-B170A263-8E09-4961-8362-911FDFFA3356Q41872064-4A654B68-99EE-470E-8093-BBCD6E8C4FE3Q42078143-A1B07552-E337-4E2B-988E-E5AF01CA7241Q48150564-263B1F82-1656-4FDE-B64A-A25BBC5D7412Q53085750-C3656854-9018-4E54-BEFD-CB0B67860623Q56700247-AB18D4DA-DDD6-4B67-A670-0621921B07EC
P2860
Deferiprone targets aconitase: implication for Friedreich's ataxia treatment
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Deferiprone targets aconitase: implication for Friedreich's ataxia treatment
@ast
Deferiprone targets aconitase: implication for Friedreich's ataxia treatment
@en
type
label
Deferiprone targets aconitase: implication for Friedreich's ataxia treatment
@ast
Deferiprone targets aconitase: implication for Friedreich's ataxia treatment
@en
prefLabel
Deferiprone targets aconitase: implication for Friedreich's ataxia treatment
@ast
Deferiprone targets aconitase: implication for Friedreich's ataxia treatment
@en
P2093
P2860
P356
P1433
P1476
Deferiprone targets aconitase: implication for Friedreich's ataxia treatment
@en
P2093
Emmanuel P Dassa
Pierre Rustin
Sergio Goncalves
Vincent Paupe
P2860
P2888
P356
10.1186/1471-2377-8-20
P577
2008-06-16T00:00:00Z
P5875
P6179
1024913202